CVE:PAS

Pascal Biosciences Competitors

C$0.08
+0.01 (+6.25 %)
(As of 04/19/2021 01:58 PM ET)
Add
Compare
Today's Range
C$0.08
Now: C$0.09
C$0.09
50-Day Range
C$0.08
MA: C$0.10
C$0.11
52-Week Range
C$0.07
Now: C$0.09
C$0.45
Volume23,463 shs
Average Volume102,234 shs
Market CapitalizationC$5.53 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Pascal Biosciences (CVE:PAS) Vs. COV, EMH, IGX, QPT, CZO, and CTX

Should you be buying PAS stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Pascal Biosciences, including Covalon Technologies (COV), Emerald Health Therapeutics (EMH), IntelGenx Technologies (IGX), Quest PharmaTech (QPT), Ceapro (CZO), and Crescita Therapeutics (CTX).

Pascal Biosciences (CVE:PAS) and Covalon Technologies (CVE:COV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Earnings & Valuation

This table compares Pascal Biosciences and Covalon Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pascal BiosciencesN/AN/AN/AC($0.02)-3.86
Covalon TechnologiesC$23.84 million1.68C$-6,144,922.00C($0.24)-6.51

Pascal Biosciences has higher earnings, but lower revenue than Covalon Technologies. Covalon Technologies is trading at a lower price-to-earnings ratio than Pascal Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pascal Biosciences and Covalon Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pascal BiosciencesN/AN/AN/A
Covalon TechnologiesN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for Pascal Biosciences and Covalon Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pascal Biosciences0000N/A
Covalon Technologies0000N/A

Summary

Pascal Biosciences beats Covalon Technologies on 2 of the 3 factors compared between the two stocks.

Emerald Health Therapeutics (CVE:EMH) and Pascal Biosciences (CVE:PAS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Earnings & Valuation

This table compares Emerald Health Therapeutics and Pascal Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emerald Health TherapeuticsC$13.02 million3.94C$-142,699,488.00C($0.70)-0.36
Pascal BiosciencesN/AN/AN/AC($0.02)-3.86

Pascal Biosciences has lower revenue, but higher earnings than Emerald Health Therapeutics. Pascal Biosciences is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Emerald Health Therapeutics and Pascal Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emerald Health Therapeutics0000N/A
Pascal Biosciences0000N/A

Profitability

This table compares Emerald Health Therapeutics and Pascal Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emerald Health TherapeuticsN/AN/AN/A
Pascal BiosciencesN/AN/AN/A

Summary

Emerald Health Therapeutics beats Pascal Biosciences on 2 of the 3 factors compared between the two stocks.

Pascal Biosciences (CVE:PAS) and IntelGenx Technologies (CVE:IGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Analyst Recommendations

This is a summary of recent recommendations for Pascal Biosciences and IntelGenx Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pascal Biosciences0000N/A
IntelGenx Technologies0000N/A

Profitability

This table compares Pascal Biosciences and IntelGenx Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pascal BiosciencesN/AN/AN/A
IntelGenx TechnologiesN/AN/AN/A

Valuation and Earnings

This table compares Pascal Biosciences and IntelGenx Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pascal BiosciencesN/AN/AN/AC($0.02)-3.86
IntelGenx TechnologiesC$1.54 million39.86C$-9,064,710.00C($0.08)-6.79

Pascal Biosciences has higher earnings, but lower revenue than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Pascal Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Pascal Biosciences beats IntelGenx Technologies on 2 of the 3 factors compared between the two stocks.

Quest PharmaTech (CVE:QPT) and Pascal Biosciences (CVE:PAS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Earnings and Valuation

This table compares Quest PharmaTech and Pascal Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest PharmaTechC$38,871.00474.71C$109.88 millionC$0.660.17
Pascal BiosciencesN/AN/AN/AC($0.02)-3.86

Quest PharmaTech has higher revenue and earnings than Pascal Biosciences. Pascal Biosciences is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quest PharmaTech and Pascal Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest PharmaTechN/AN/AN/A
Pascal BiosciencesN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Quest PharmaTech and Pascal Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest PharmaTech0000N/A
Pascal Biosciences0000N/A

Summary

Quest PharmaTech beats Pascal Biosciences on 3 of the 3 factors compared between the two stocks.

Pascal Biosciences (CVE:PAS) and Ceapro (CVE:CZO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Pascal Biosciences and Ceapro, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pascal Biosciences0000N/A
Ceapro0000N/A

Earnings and Valuation

This table compares Pascal Biosciences and Ceapro's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pascal BiosciencesN/AN/AN/AC($0.02)-3.86
CeaproC$16.14 million3.56C$2.56 millionC$0.0322.42

Ceapro has higher revenue and earnings than Pascal Biosciences. Pascal Biosciences is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pascal Biosciences and Ceapro's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pascal BiosciencesN/AN/AN/A
CeaproN/AN/AN/A

Summary

Ceapro beats Pascal Biosciences on 3 of the 3 factors compared between the two stocks.

Pascal Biosciences (CVE:PAS) and Crescita Therapeutics (TSE:CTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Pascal Biosciences and Crescita Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pascal BiosciencesN/AN/AN/A
Crescita TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares Pascal Biosciences and Crescita Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pascal BiosciencesN/AN/AN/AC($0.02)-3.86
Crescita TherapeuticsC$15.64 million1.06C$41,296.00C$0.00400.00

Crescita Therapeutics has higher revenue and earnings than Pascal Biosciences. Pascal Biosciences is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Pascal Biosciences and Crescita Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pascal Biosciences0000N/A
Crescita Therapeutics0000N/A

Summary

Crescita Therapeutics beats Pascal Biosciences on 3 of the 3 factors compared between the two stocks.


Pascal Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
COV
Covalon Technologies
0.6$1.55+3.2%C$37.44 millionC$23.84 million-6.51Gap Down
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.25+2.0%C$34.02 millionC$13.02 million-0.36Gap Up
IGX
IntelGenx Technologies
0.9$0.55+1.8%C$30.87 millionC$1.54 million-6.79
QPT
Quest PharmaTech
0.8$0.11+13.6%C$21.76 millionC$38,871.000.17Gap Down
CZO
Ceapro
0.7$0.74+1.4%C$21.65 millionC$16.14 million22.42
CTX
Crescita Therapeutics
0.6$0.80+6.3%C$16.52 millionC$15.64 million400.00
KNE
Kane Biotech
0.4$0.20+2.6%C$14.12 millionC$1.34 million-5.57
GSD
Devonian Health Group
0.5$0.26+3.8%C$13.96 millionC$1.59 million-5.42High Trading Volume
NSP
Naturally Splendid Enterprises
0.6$0.06+0.0%C$11.06 millionC$2.03 million-1.40
MPH
Medicure
0.7$1.63+1.2%C$10.80 millionC$12.71 million-1.05Gap Up
BTI
Bioasis Technologies
0.7$0.34+1.5%C$10.16 millionC$4.12 million30.45Gap Down
HEM
Hemostemix
0.6$0.33+6.2%C$9.07 millionN/A-1.93Gap Down
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.38+2.6%C$6.94 millionC$5.60 million7.04
IOT
Innovotech
0.8$0.17+5.9%C$6.52 millionC$1.04 million85.00Gap Down
BCT
BriaCell Therapeutics
0.5$3.56+7.3%C$4.48 millionN/A-1.15
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$46.34+2.6%C$0.00C$267.59 million50.92
LTY
Liberty Biopharma
0.6$2.00+100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49+6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32+5.3%C$0.00N/A0.00News Coverage
Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.